NCT01234324已完成2 期
An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination With Epirubicin, Cisplatin and Capecitabine (ECX) Versus ECX Alone in Subjects With Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 171
- 试验地点
- 1
- 主要终点
- Frequency of pT3/T4 categories after surgery
研究概览
简要总结
That panitumumab in combination with Epirubicin, Cisplatin and Capecitabine (ECX) will safely decrease the frequency of pT3/T4 below that of ECX alone in subjects with locally advanced adenocarcinoma of the stomach and gastroesophageal junction.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Competent to comprehend, sign, and date an IEC-approved informed consent form, written informed consent.
- •Of either gender and aged 18 years or more.
- •Diagnosed with histologically confirmed adenocarcinoma of the stomach or the gastroesophageal junction of Type I/II/III according to the classification of Siewert et al,
- •Stage uT/3 or 4 N0/+ and M0 disease evaluated by endoscopic ultrasound, spiral computed tomography of the chest, abdomen and pelvis and by laparoscopy in uT3/T4 tumors.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Leucocyte count > 3,000/mm
- •Platelet count ≥100,000/mm
- •Haemoglobin ≥10 g/dl.
- •Serum creatinine ≤ 1.5x of upper limit of normal (ULN).
- •Creatinine clearance > 60 ml/kg/min measured either by 24-h urine sampling or calculated by using the Cockcroft-Gault formula .
- •Aspartate aminotransferase (AST) ≤3 x ULN.
- •Alanine aminotransferase (ALT) ≤3 x ULN.
- •Bilirubin ≤ 1.5 x ULN.
- •Magnesium ≥ lower limit of normal.
- •Calcium ≥ lower limit of normal.
- •Subject is deemed a good candidate for surgery.
排除标准
- •Any metastatic disease.
- •Other malignant tumours less than five years old. Exceptions include basocellular carcinoma, in situ cancer of the cervix of the uterus, or any curatively-treated other malignancies without evidence of disease for more than five years.
- •Significant ascites or pleural effusion.
- •Prior anti-EGFr antibody therapy (e.g. cetuximab) or treatment with small molecule EGFr tyrosine kinase inhibitors (e.g. erlotinib).
- •Prior chemotherapy, radiotherapy or antibody therapy for gastric cancer or cancer of the gastro-oesophageal junction.
- •Concomitant therapy with sorivudine or analogue compounds.
- •Known previous or ongoing abuse of narcotic drug, other medication or alcohol.
- •Significant cardiovascular disease including New York Heart Association (NYHA) grade II or greater congestive heart failure, peripheral arterial occlusive disease stage II or greater, symptomatic coronary heart disease, insufficiently treated arterial hypertension, unstable angina or myocardial infarction within 12 months before initiating study treatment or a history of ventricular arrhythmia.
- •History or evidence upon physical examination of CNS disease unless adequately treated, seizure not controlled with standard medical therapy, or history of stroke.
- •History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest CT scan.
- •Pre-existing polyneuropathy grade >1 according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE), except for loss of tendon reflex as the only symptom.
- •Treatment for systemic infection within 14 days before initiating study treatment.
- •Active inflammatory bowel disease, serious gastric ulceration or other bowel disease causing chronic diarrhoea (defined as > 4 loose stools per day).
- •Suspected or known dihydropyrimidine dehydrogenase deficiency (DPD).
- •Thrombosis or severe bleeding within six months prior to entry into the study (except for bleeding of the tumour before its surgical resection), evidence of bleeding diathesis or coagulopathy, or current or recent (within 10 days prior to initiation of study treatment) use of full-dose oral or parenteral anticoagulants for therapeutic purposes.
- •History of any medical condition that may increase the risks associated with study participation or may interfere with the interpretation of the study results.
- •Known positive test for human immunodeficiency virus infection, hepatitis C virus or chronic active hepatitis B infection.
- •Known allergy to the investigational product, to any of its excipients, to monoclonal antibodies, or to any of the components of the chemotherapy regimen.
- •Any co-morbid disease that would increase risk of toxicity.
- •Any kind of disorder that compromises the ability of the subject to give written informed consent and/or comply with the study procedures.
- •Any investigational agent or participation in another clinical trial within 30 days prior to randomisation.
- •Must not have had a major surgical procedure within 28 days of randomisation.
- •Subject who is pregnant or breast feeding.
- •Woman or man of childbearing potential not consenting to use adequate contraceptive precautions (intrauterine contraceptive device, contraceptive implants, injectables (hormonal depot), transdermal hormonal contraception (contraceptive patch), sexual abstinence or vasectomised partner) during the course of the study and for six months after the last study drug administration for women and men. Post-menopausal women must have been amenorrheic for at least 12 months to be considered of non-child-bearing potential.
- •Subject unwilling or unable to comply with study requirements.
- •Hearing impairment
研究组 & 干预措施
Arm 1: ECX + Panitumumab
Experimental
干预措施: Epirubicin, Cisplatin, Capecitabine, Panitumumab (Drug)
Arm 2: EXC alone
Active Comparator
干预措施: Epirubicin, Cisplatin, Capecitabine (Drug)
结局指标
主要结局
Frequency of pT3/T4 categories after surgery
时间窗: after 9 weeks treatment
次要结局
- Frequencies of pN2/N3 categories after surgery(After 9 weeks treatment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)Metastatic Colorectal CancerNCT00958386Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)61
已完成
2 期
Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only MetastasesColorectal CancerNCT00885885Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)80
终止
2 期
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung CancerRecurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerNCT00976677National Cancer Institute (NCI)10
已完成
3 期
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation StudyColorectal CancerNCT00115765Amgen1,053
招募中
2 期
Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic CancerPancreatic Adenocarcinoma MetastaticNCT06051851The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School177